Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 + Lenvatinib in Advanced NSCLC
NCT04777084Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of reozalimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Aug 2021; status: recruiting.
02
Drugs
reozalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04777084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777084.